Format

Send to

Choose Destination
Chest. 2012 Apr;141(4):923-928. doi: 10.1378/chest.11-0483. Epub 2011 Oct 26.

The role of target therapies in schistosomiasis-associated pulmonary arterial hypertension.

Author information

1
Cardio-Pulmonary Department, Heart Institute, University of São Paulo Medical School, São Paulo, Brazil. Electronic address: cjcfernandes@yahoo.com.br.
2
Cardio-Pulmonary Department, Heart Institute, University of São Paulo Medical School, São Paulo, Brazil.

Abstract

BACKGROUND:

Schistosomiasis-associated pulmonary arterial hypertension (Sch-PAH) may be one of the most prevalent forms of pulmonary arterial hypertension (PAH) worldwide. However, the clinical and hemodynamical response to specific PAH therapy in Sch-PAH is not known.

METHODS:

We retrospectively analyzed the charts of all patients with Sch-PAH who initiated specific PAH treatment between June 2003 and June 2010 in a single PAH reference center in São Paulo, Brazil. Clinical and hemodynamical data were retrospectively collected and evaluated in two periods: baseline and posttreatment.

RESULTS:

The study population consisted of 12 patients with Sch-PAH. They were treated with phosphodiseterase-5 inhibitors (seven patients), endothelin receptor antagonists (four patients), or combination therapy (one patient). Mean treatment period was 34.9 ± 15.5 months. Patients with Sch-PAH presented significant improvements in terms of functional class, 6-min walk test distance (439 ± 85 to 492 ± 79 m, P = .032), cardiac index (2.66 ± 0.59 to 3.08 ± 0.68 L/min/m(2), P = .028), and indexed pulmonary vascular resistance (20.7 ± 11.6 to 15.9 ± 9 W/m(2), P = .038) with the introduction of specific PAH treatment.

CONCLUSIONS:

We conclude that specific PAH therapy may be of benefit to patients with Sch-PAH, considering clinical, functional, and hemodynamic parameters.

PMID:
22030800
DOI:
10.1378/chest.11-0483
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center